Alphabet's AI drug discovery startup, Isomorphic Labs, a spinout from Google DeepMind and powered by the AlphaFold protein-folding technology, is preparing to initiate its first human clinical trials of AI-designed drugs later this year. The company, which recently secured $600 million in funding and formed partnerships with pharmaceutical giants Novartis and Eli Lilly, aims to revolutionize drug development by making it up to ten times faster and 90% cheaper. The initial trials will focus on AI-designed cancer treatments, leveraging algorithms to design molecules that could potentially accelerate lab-to-patient cycles and improve precision in targeting diseases. Colin Murdoch, president of Isomorphic Labs, has indicated that the company is "getting very close" to starting these human studies. This advancement represents a major milestone in AI-driven medicine, with ambitions to eventually design treatments on demand and possibly address a wide range of diseases. Concurrent developments in AI-powered immunotherapy, including T-cell receptor (TCR) therapies enhanced by AI algorithms such as "BATMAN," suggest a broader trend toward precision and personalized cancer treatments using artificial intelligence.